These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 33025342

  • 1. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
    Tran JQ, Zhang P, Walker S, Ghosh A, Syto M, Wang X, Harris S, Palmisano M.
    Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
    [Abstract] [Full Text] [Related]

  • 2. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
    Tran JQ, Zhang P, Ghosh A, Liu L, Syto M, Wang X, Palmisano M.
    Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
    [Abstract] [Full Text] [Related]

  • 3. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ.
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [Abstract] [Full Text] [Related]

  • 4. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
    Briggs E, Chapel S, Zhang P, Palmisano M, Tran JQ.
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
    [Abstract] [Full Text] [Related]

  • 5. Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B.
    Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D.
    Drug Metab Dispos; 2021 Aug; 49(8):601-609. PubMed ID: 34011531
    [Abstract] [Full Text] [Related]

  • 6. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ, Hartung JP, Tompkins CA, Frohna PA.
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
    [Abstract] [Full Text] [Related]

  • 7. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA.
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [Abstract] [Full Text] [Related]

  • 8. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS.
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [Abstract] [Full Text] [Related]

  • 9. Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
    Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, Peach RJ, Gujrathi S, Frohna PA.
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):263-276. PubMed ID: 28783871
    [Abstract] [Full Text] [Related]

  • 10. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
    Selkirk JV, Yan YG, Ching N, Paget K, Hargreaves R.
    Eur J Pharmacol; 2023 Feb 15; 941():175442. PubMed ID: 36470447
    [Abstract] [Full Text] [Related]

  • 11. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
    Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P.
    Antimicrob Agents Chemother; 2013 Jul 15; 57(7):3060-6. PubMed ID: 23612197
    [Abstract] [Full Text] [Related]

  • 12. Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
    Howard DR, Haribhakti R, Kittner B, Agrawala P.
    Curr Med Res Opin; 2005 May 15; 21(5):769-76. PubMed ID: 15969876
    [Abstract] [Full Text] [Related]

  • 13. A randomized, placebo-controlled, exploratory trial of Ibuprofen and pseudoephedrine in the treatment of primary nocturnal enuresis in children.
    Gelotte CK, Prior MJ, Gu J.
    Clin Pediatr (Phila); 2009 May 15; 48(4):410-9. PubMed ID: 19258524
    [Abstract] [Full Text] [Related]

  • 14. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
    Thébault JJ, Guillaume M, Levy R.
    Pharmacotherapy; 2004 Oct 15; 24(10):1295-305. PubMed ID: 15628826
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
    Azzaro AJ, VanDenBerg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ.
    J Clin Pharmacol; 2007 Aug 15; 47(8):978-90. PubMed ID: 17554106
    [Abstract] [Full Text] [Related]

  • 16. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G.
    CNS Drugs; 2018 Nov 15; 32(11):1053-1067. PubMed ID: 30374683
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug 15; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S.
    Hum Reprod; 2017 Aug 01; 32(8):1639-1647. PubMed ID: 28591833
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.
    Flanagan S, Minassian SL, Prokocimer P.
    J Clin Med; 2018 Jun 14; 7(6):. PubMed ID: 29899212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.